A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-687 for the Treatment of Diabetic Macular Edema (DME)
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2018
At a glance
- Drugs THR 687 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Oxurion
- 19 Oct 2018 According to an Oxurion media release, initial results from this clinical study are anticipated by the end of the second half of 2019.
- 20 Sep 2018 According to an Oxurion media release, first patient has been enrolled.
- 20 Sep 2018 Status changed from not yet recruiting to recruiting, according to an Oxurion media release.